Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.45 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.45 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.45 |
| ▸ | MMP8 | P22894 | 9/20 | 0.42 |
| ▸ | ANPEP | P15144 | 1/20 | 0.40 |
| ▸ | ECE1 | P42892 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL489725 | 0.80 | MMP8 (0.49) | ERAP2ERAP1LNPEPMMP8 | |
| SCHEMBL489466 | 0.77 | MMP8 (0.45) | ERAP2ERAP1LNPEPMMP8ECE1 | |
| SCHEMBL489469 | 0.76 | MMP8 (0.45) | ERAP2ERAP1LNPEPMMP8ANPEP | |
| SCHEMBL1257949 | 0.75 | AGTR1 (0.49) | ERAP2ERAP1LNPEPMMP8 | |
| SCHEMBL2393693 | 0.74 | ERAP2 (0.42) | ERAP2ERAP1LNPEPMMP8 | |
| SCHEMBL8508958 | 0.66 | LTB4R2 (0.44) | — | |
| SCHEMBL489832 | 0.66 | MMP8 (0.53) | ERAP2ERAP1LNPEPMMP8 | |
| SCHEMBL489537 | 0.65 | LTB4R2 (0.50) | — | |
| SCHEMBL28053850 | 0.64 | KMT2A (0.47) | — | |
| SCHEMBL489507 | 0.63 | MME (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8236839-B2 | Dual-acting antihypertensive agents | THERAVANCE, INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-20120088919-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-8106082-B2 | Dual-acting antihypertensive agents | THERAVANCE, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-20110021585-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-7834041-B2 | Dual-acting antihypertensive agents | THERAVANCE, INC. (US) | 2010-11-16 | — | — | US | disclosed |
| US-20090093417-A1 | Dual-acting antihypertensive agents | THERAVANCE, INC. | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093417-A1 | Dual-acting antihypertensive agents | AGTR1, REN, AGTR2 | ERAP2 374/4885ERAP1 300/4885LNPEP 650/4885 |
| US-20110021585-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | AGTR1, REN, AGTR2 | ERAP2 374/4885ERAP1 300/4885LNPEP 650/4885 |
| US-20120088919-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | AGTR1, REN, AGTR2 | ERAP2 374/4885ERAP1 300/4885LNPEP 650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.